Drug Search Results
More Filters [+]

Sulodexide

Alternative Names: sulodexide
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Antithrombin Modulator,Thrombin Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Bulgaria | Czech | Hungary | Italy | Korea | Lebanon | Malaysia | Mexico | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Spain | Thailand | Tunisia | Turkey | Ukraine | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Akebia
Company Location: CAMBRIDGE MA 02142
Company CEO: John P. Butler
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sulodexide

Countries in Clinic: Mexico

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Post Acute COVID-19 Syndrome|Thrombosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CMN-01-2021

P3

Completed

Post Acute COVID-19 Syndrome|Thrombosis

2024-02-07

VEINS (VEnous INvestigation with Sulodexide)

P3

Completed

Unknown

2022-08-31

Recent News Events